Le Lézard
Classified in: Tourism and vacations, Transportation, Health, Covid-19 virus
Subject: SVY

Post-pandemic Growth Opportunity Analysis of the Global Airport & Airline Industry, 2020 Report - Contactless Boarding, Revenue Management, and Network Planning will Play a Key Role


DUBLIN, Sept. 24, 2020 /PRNewswire/ -- The "Post-pandemic Growth Opportunity Analysis of the Global Airport & Airline Industry" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Before the global COVID-19 pandemic hit, the aviation industry had anticipated high passenger volume and aircraft fleet growth over the next decade.

Now, however, the industry is suddenly facing a new environment where capacities are reduced and passenger demand is down for the foreseeable future. If the global situation results in prolongs lock-downs and delayed development of vaccination, airlines' financial strength will be greatly impacted and change the industry landscape. Privately operated airports will face difficulties in keeping costs down when there is negligible revenue generation.

Also, the uncertain nature of this pandemic has severely marred passenger confidence, which may take time to rebuild post-crisis. Weak passenger confidence in travel and declining economic conditions among many countries will impact the total number of passengers travelling, in both the domestic and international segments. Passenger numbers are estimated to reach pre-pandemic levels only after a couple of years.

Airlines and airports must seize digital opportunities to navigate this uncertain period and ensure the smooth re-establishment of air travel. Digital solutions will enable both airlines and airports to plan and align their resources with the sudden decline in demand; these tools will play a key role as airlines and airports scale up their operations to match the rise in travel. The aviation industry will require higher levels of collaboration between software providers, hardware providers, and master integrators to meet business requirements and provide seamless services. New technologies such as the Internet of Things (IoT) and big data analytics will play a major role at airports in optimizing operations and ensuring efficient health screening at key touch points.

Airlines have a high level of fixed costs that negatively impact liquidity and cash flow. In this situation, airlines and airports will need to negotiate and strike new deals that enable them to reduce fixed costs. Operational costs that are variable can be kept low by optimizing resources and achieving operational efficiency with the help of digital solutions, which will also help airlines and airports ramp up operations as demand for air travel grows.

The European region has been volatile for the last few years, with multiple airline bankruptcies. The pandemic will lead to a consolidated market in Europe, similar to the North American market. Countries with high levels of domestic demand such as the United States, India, China, and Latin American countries will begin to mitigate the impact of the pandemic as restrictions on domestic travel are lifted earlier than for international travel, and the robust air travel market will grow as the external situation improves (e.g., factors like vaccination development and recovering economic conditions).

The top measures that will ensure business continuity are fiscal discipline, renegotiation of contracts to stabilize fixes costs, and protection of employee welfare. Airlines and airports must be ready to resume operations in a scaled manner to ensure that rebound demand is captured effectively. Digital solutions in areas of operational efficiency, contactless boarding, revenue management, and network planning will play a key role in stimulating demand, right-sizing operations, and reviving revenue growth.

Key Topics Covered:

1. Growth Environment

2. Growth Opportunities

3. Companies to Action

4. Appendix: Growth Pipeline Engine

For more information about this report visit https://www.researchandmarkets.com/r/kr66bj

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 01:00
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. ? ?  Q1 2024? Q1 2023? % change? ?m? ?m? ActualCER1Growth...

23 avr 2024
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into...

23 avr 2024
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

23 avr 2024
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...

23 avr 2024
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

23 avr 2024
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...



News published on and distributed by: